Collections work, but volumes must prove it
- Pediatrix now focuses on hospital-based care after exiting almost all office-based practices by December 31, 2024.
- Q1 2026 same-unit revenue rose 2.8%, but patient service volumes fell 1.6%.
- Better collections and reimbursement drove the quarter, with DSO staying low at 42.5 days.
- Management says the volume dip is not a trend, but also says RCM cash collection gains should fade through 2026.
- Texas is a real concentration risk, since it generated about 32% of 2024 continuing net revenue.
The turnaround faces a volume test
Pediatrix has become a cleaner company. It finished its plan to leave almost all office-based practices, except maternal-fetal medicine, at the end of 2024. The new focus is hospital-based newborn, maternal-fetal, and pediatric subspecialty care.
The bull case is that the simpler model is working. Same-unit revenue grew 6.2% in 2025, and DSO, which means days to collect bills, fell to 42.8 days at year-end 2025. In Q1 2026, DSO stayed strong at 42.5 days. That supports the idea that the new hybrid revenue cycle management setup is helping Pediatrix collect cash faster.
The bear case is that Q1 2026 growth did not come from more patients. Same-unit revenue rose 2.8%, but that was more than explained by a 4.4% gain from reimbursement-related items, partly offset by a 1.6% drop from patient service volumes. Management said recent volume results do not show a trend. Still, if volumes stay weak, the story depends too much on collections, acuity, fees, and payor mix.
The next test is the second half of 2026. Management said strong RCM cash collections should tail off as the year goes on, while it kept a flat pricing outlook. Pediatrix also sees a major chance to expand teleservices and obstetrics nationwide, but investors still need a clearer timeline and revenue size for that idea.
Doctors, hospitals, and billing
Pediatrix makes money when its affiliated physicians provide specialized care and the company bills insurers, patients, and government programs. Its network works across 36 states, mainly in hospital-based settings.
The core work includes neonatal intensive care for premature or medically fragile babies, maternal-fetal care for complicated pregnancies, obstetrical services, and other pediatric subspecialty care. The company has narrowed the portfolio so management can focus on the hospital model.
Revenue depends on two basic levers: patient volume and payment per case. Payment per case can move with payor mix, acuity, administrative fees, collections, and rules set by insurers or government programs.
The model breaks if either lever turns against Pediatrix. Lower patient volume cuts the amount of care billed. Lower reimbursement, slower cash collection, or a legal cap on out-of-network payments can reduce how much cash the company keeps from that care.
Care lines that drive the bills
Neonatal clinical care
This is care in hospital neonatal intensive care units for premature babies or babies with medical problems. It is central to Pediatrix's identity and billing base.
Maternal-fetal medicine
These doctors care for mothers with complicated pregnancies. Pediatrix kept this office-linked area while exiting almost all other office-based practices.
Obstetrical care
Management sees a chance to expand obstetrics across the country. The idea could add growth, but the company has not yet given a clear revenue timeline.
Pediatric subspecialties
Pediatrix also provides other specialty care for children. This remains part of the service mix, though the company is narrowing around hospital-based services.
Teleservices
Telehealth-style services could let Pediatrix support more sites without the same physical footprint. Management called nationwide expansion a major opportunity in Q1 2026.
One reported business, many care settings
Pediatrix reports as a single segment. The Q1 2026 view is for the continuing physician services business, after the company completed its exit from almost all office-based practices by December 31, 2024.
What could break the case
Volume weakness becomes real
High impact · Medium oddsQ1 2026 same-unit revenue growth was held back by a 1.6% drop tied to patient service volumes. Management said recent volume results do not show a trend, but the numbers still need to improve. If patient days or visits keep falling, collections alone may not carry growth.
Collection gains fade
High impact · Medium oddsThe new hybrid revenue cycle management system has helped DSO fall to 42.5 days. Management also said RCM cash collection strength should tail off through the year. If that happens while volumes stay weak, same-unit revenue growth may slow further.
Payor and government pressure
High impact · Medium oddsPediatrix depends on reimbursement from commercial insurers and government programs. A shift toward more government-sponsored patients can lower average payment rates. The No Surprises Act, ACA changes, Medicaid changes, or subsidy lapses could also affect what the company collects.
Texas concentration
Medium impact · Medium oddsIn 2024, about 67% of continuing net revenue came from the five largest states, and Texas alone was about 32%. That makes local hospital relationships, state policy, and regional birth trends more important than they look at first glance.
Malpractice and legal costs
Medium impact · Medium oddsPediatrix works in high-risk clinical areas, including newborn intensive care and complicated pregnancies. The company is regularly involved in medical malpractice claims and carries a meaningful self-insured retention through a captive subsidiary. Large claims or higher insurance costs could hurt margins.
In one breath
What does Pediatrix Medical Group do?
Pediatrix provides physician services for newborn, maternal-fetal, obstetrical, and pediatric specialty care. Much of the work happens in hospitals, including neonatal intensive care units.
Why is patient volume so important for MD stock?
Pediatrix bills for care delivered by its affiliated doctors. If patient service volumes fall, revenue growth must come from reimbursement, collections, or mix, which may be harder to repeat.
What changed after the restructuring?
Pediatrix exited almost all office-based practices, other than maternal-fetal medicine, by December 31, 2024. The company now has a simpler focus on hospital-based services and cash collection.
What is the main 2026 question for Pediatrix?
The key question is whether patient volumes recover before RCM cash collection gains fade. If they do not, the recent same-unit revenue growth may look less durable.